585 related articles for article (PubMed ID: 18399711)
1. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Stangier J
Clin Pharmacokinet; 2008; 47(5):285-95. PubMed ID: 18399711
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
Eisert WG; Hauel N; Stangier J; Wienen W; Clemens A; van Ryn J
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
Blommel ML; Blommel AL
Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Stangier J; Eriksson BI; Dahl OE; Ahnfelt L; Nehmiz G; Stähle H; Rathgen K; Svärd R
J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
[TBL] [Abstract][Full Text] [Related]
11. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
[TBL] [Abstract][Full Text] [Related]
12. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
[TBL] [Abstract][Full Text] [Related]
14. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate in venous thromboembolism.
Ferrer E
Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran etexilate.
Sanford M; Plosker GL
Drugs; 2008; 68(12):1699-709. PubMed ID: 18681492
[TBL] [Abstract][Full Text] [Related]
17. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran etexilate: a new thrombin inhibitor.
Verma AK
Med J Aust; 2010 Apr; 192(7):407-12. PubMed ID: 20367591
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
Cheng JW; Vu H
Clin Ther; 2012 Apr; 34(4):766-87. PubMed ID: 22444784
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
